Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Propionyl-CoA carboxylase alpha chain, mitochondrial (PCCA), is the alpha subunit of a biotin-dependent mitochondrial enzyme critical for the carboxylation of propionyl-CoA to (S)-methylmalonyl-CoA, an essential step in the catabolism of odd-chain fatty acids and branched-chain amino acids. The enzyme is a heterododecamer, composed of six alpha (PCCA) and six beta (PCCB) subunits, and requires biotin as a cofactor. Mutations in PCCA cause propionic acidemia, an autosomal recessive inborn error of metabolism characterized by life-threatening episodes of metabolic acidosis and long-term neurological and systemic complications. While not currently a target for small molecule drugs, PCCA is fundamental to cellular intermediary metabolism and serves as a diagnostic marker in metabolic disease.
No targeted pharmacological mechanism of action as a drug target. Disease management focuses on dietary restriction or removing propionyl-CoA substrate source.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Propionyl-CoA carboxylase alpha chain, mitochondrial (PCCA).